Cell type-specific expression, regulation and compensation of CDKL5 activity in mouse brain

Margaux Silvestre,Kelvin Dempster,Simeon R. Mihaylov,Suzanne Claxton,Sila K. Ultanir

DOI: https://doi.org/10.1038/s41380-024-02434-7

IF: 11

2024-02-08

Molecular Psychiatry

Abstract:CDKL5 is a brain-enriched serine/threonine kinase, associated with a profound developmental and epileptic encephalopathy called CDKL5 deficiency disorder (CDD). To design targeted therapies for CDD, it is essential to determine where CDKL5 is expressed and is active in the brain and test if compensatory mechanisms exist at cellular level. We generated conditional Cdkl5 knockout mice in excitatory neurons, inhibitory neurons and astrocytes. To assess CDKL5 activity, we utilized a phosphospecific antibody for phosphorylated EB2, a well-known substrate of CDKL5. We found that CDKL5 and EB2 pS222 were prominent in excitatory and inhibitory neurons but were not detected in astrocytes. We observed that approximately 15–20% of EB2 pS222 remained in Cdkl5 knockout brains and primary neurons. Surprisingly, the remaining phosphorylation was modulated by NMDA and PP1/PP2A in neuronal CDKL5 knockout cultures, indicating the presence of a compensating kinase. Using a screen of candidate kinases with highest homology to the CDKL5 kinase domain, we found that CDKL2 and ICK can phosphorylate EB2 S222 in HEK293T cells and in primary neurons. We then generated Cdkl5/Cdkl2 dual knockout mice to directly test if CDKL2 phosphorylates EB2 in vivo and found that CDKL2 phosphorylates CDKL5 substrates in the brain. This study is the first indication that CDKL2 could potentially replace CDKL5 functions in the brain, alluding to novel therapeutic possibilities.

biochemistry & molecular biology,neurosciences,psychiatry

What problem does this paper attempt to address?

The problems that this paper attempts to solve are about the specific cell types of CDKL5 expression and activity in the brain, and whether there are compensatory mechanisms to replace the function of CDKL5. Specifically:

1. **Determine the cell - specific expression and activity of CDKL5**: Researchers generated conditional knockout mouse models (knocking out the Cdkl5 gene in excitatory neurons, inhibitory neurons, and astrocytes respectively), combined with single - cell RNA sequencing data, to determine the specific location of CDKL5 expression and activity in the brain. They found that CDKL5 is mainly expressed and active in excitatory and inhibitory neurons, while its expression and activity were not detected in astrocytes.

2. **Explore the compensatory mechanisms of CDKL5 function**: Researchers further investigated whether there are other kinases that can compensate for the function of CDKL5 in the absence of CDKL5. By screening candidate kinases with the highest homology to the kinase domain of CDKL5, they found that CDKL2 and ICK can phosphorylate the EB2 S222 site in HEK293T cells and primary neurons. Further, by generating a Cdkl5/Cdkl2 double - knockout mouse model, researchers confirmed that CDKL2 can phosphorylate CDKL5 substrate proteins such as EB2 and MAP1S in vivo, indicating that CDKL2 may partially replace the function of CDKL5.

These findings not only help to understand the mechanism of CDKL5 in the brain but also provide potential targets for the development of new therapies for CDKL5 deficiency (CDD).